Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Citrulline Allo. Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified January 2011 by University Hospital, Clermont-Ferrand.
Recruitment status was:  Recruiting
Information provided by:
University Hospital, Clermont-Ferrand Identifier:
First received: September 9, 2008
Last updated: January 18, 2011
Last verified: January 2011
determine the interest of the dosage of citrullinemia to monitor the bowel damage after allogeneic bone marrow transplantation in children.

Benign Disease

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Evaluation of Citrullinemia as a Marker of Bowel Damage After Allogeneic Bone Marrow Transplantation in Children

Resource links provided by NLM:

Further study details as provided by University Hospital, Clermont-Ferrand:

Primary Outcome Measures:
  • Citrullinemia (weekly) [ Time Frame: weekly ]

Secondary Outcome Measures:
  • Gastro-intestinal complications in children following allogeneic bone marrow transplantation [ Time Frame: following allogenic bone marrow transplantation ]

Estimated Enrollment: 30
Study Start Date: April 2008
Estimated Study Completion Date: September 2009
Estimated Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)

Detailed Description:

30 children included. Dosage of citrullinemia on day -7, day 0 and every week up to 100 days after BMT. Histological examination and extensive infectious screening in case of persistent digestive symptoms (more than 3 days).

Two groups of patients regarding on digestive involvement. Comparison of the values of citrullinemia between these two groups.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Inclusion Criteria:

  • 0 to 18 years
  • allogeneic bone marrow transplantation for malignant or benign disease
  • affiliation to French sécurité sociale
  • parent's consent

Exclusion Criteria:

  • severe gastro-intestinal involvement before transplant
  • previous digestive surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00751452

Contact: Lacarin Patrick

Etienne MERLIN Recruiting
Clermont-Ferrand, France, 63003
Sponsors and Collaborators
University Hospital, Clermont-Ferrand
Principal Investigator: Merlin Etienne, Dr University Hospital, Clermont-Ferrand
  More Information

Responsible Party: Merlin Etienne, CHU Clermont-Ferrand Identifier: NCT00751452     History of Changes
Other Study ID Numbers: CHU-0040
Study First Received: September 9, 2008
Last Updated: January 18, 2011

Keywords provided by University Hospital, Clermont-Ferrand:
Allogeneic bone marrow transplantation
Intestinal damage
Graft versus Host Disease
0 to 18 years old

Additional relevant MeSH terms:
Urea Cycle Disorders, Inborn
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Genetic Diseases, Inborn
Metabolic Diseases processed this record on May 25, 2017